

Panel 4: Advancing Discovery to First-In-Human Clinical Trials for New Medical Products

Moderators:

Jay Bradner, MD - President of Novartis Institutes for Biomedical Research

Joseph Wu, MD, PhD - Director of the Stanford Cardiovascular Institute

Panelists:

Hal Barron, MD - Chief Scientific Officer at GlaxoSmithKline

Tejal Desai, PhD - Chair, Bioengineering and Therapeutic Sciences at UCSF

Mathai Mammen, MD, PhD - Global Head of Research and Development at Janssen

Peter Marks, MD, PhD - Director of Center for Biologics Evaluation and Research at FDA

- **Which emerging capabilities promise to accelerate and improve the chances of success from discovery to first in human clinical trials?**
- **For innovative new products, how should the FDA acquire the scientific knowledge necessary to make good decisions about safety and efficacy?**
- **How can stakeholders play a role in supporting regulatory science outside the context of a specific product?**